Remove Pharmaceutical Companies Remove Vaccines Remove Webinar
article thumbnail

Barriers are limiting UK childhood vaccination, say doctors

pharmaphorum

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

ACIP backs block on flu vaccines with thimerosal additive

pharmaphorum

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vaccines trials in the COVID-19 era and tech’s role in speeding studies

pharmaphorum

This pharmaphorum webinar will take place on 8th April and comes as the COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus vaccine. So, what is technology’s role in supporting the faster evaluation of vaccines?

article thumbnail

Will pharma finally score a policy win for 340B?

PharmaVoice

Either way, reforms to the 340B program, which was created by Congress in 1992 and requires pharmaceutical companies to provide outpatient drug discounts to safety net hospitals, could be on the table.

Hospitals 214
article thumbnail

GRIN Therapeutics: Seeking to address unmet needs in rare neurodevelopmental disorders

pharmaphorum

Skip to main content Monday 30 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

UK follows through on doubling of statutory scheme rate

pharmaphorum

Skip to main content Wednesday 11 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

article thumbnail

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Pharmacy Times

This is progressing through a phase 3 trial and includes comparator arms with standard-of-care treatments like daratumumab, bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies), and lenalidomide. 2 We’re still trying to figure out where these new treatments best fit.